Zobrazeno 1 - 10 of 36 pro vyhledávání: '"Gabriela Dieguez"'
1
Akademický článek
The Effects of Adverse Events and Associated Costs on Value-Based Care for Metastatic Pancreatic Ductal Adenocarcinoma
Autor: Prachi Bhatt, Jared Hirsch, Paul Cockrum, George Kim, Gabriela Dieguez
Publikováno v: Journal of Health Economics and Outcomes Research, Vol 11, Iss 2 (2024)
**Background:** Rising oncology healthcare costs have led to value-based care reimbursement models that coordinate care and improve quality while reducing overall spending. These models are increasingly important for traditional Medicare and other pa
Externí odkaz: https://doaj.org/article/981728d2e15f4c05afd6b72dae391b65
Zobrazit plný text záznamu
4
Costs by Site of Service for Commercially-Insured Patients with Metastatic Pancreatic Cancer Receiving Guideline-Recommended Chemotherapy: Comparing Community Oncology and Hospital Outpatient Settings
Autor: Samantha Tomicki, Gabriela Dieguez, David DeStephano, Melody Chang, Paul Cockrum
Publikováno v: ClinicoEconomics and Outcomes Research. 14:653-663
Samantha Tomicki,1 Gabriela Dieguez,1 David DeStephano,1 Melody Chang,2 Paul Cockrum3 1Milliman, Inc, New York, NY, USA; 2American Oncology Network, Fort Meyers, FL, USA; 3Ipsen Biopharmaceuticals, Inc, Cambridge, MA, USACorrespondence: Gabriela Dieg
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56825e4ff491fc12295b8c0a025f25e0
https://doi.org/10.2147/ceor.s373316
Zobrazit plný text záznamu
6
Characterizing platinum sensitivity among Medicare FFS patients with limited versus extensive-stage small cell lung cancer receiving NCCN category 1 preferred regimens
Autor: Paul Cockrum, Gabriela Dieguez, Rebecca A. Smith, Robert A. Ramirez
Publikováno v: Journal of Clinical Oncology. 40:e20601-e20601
e20601 Background: There is limited research evaluating real-world platinum sensitivity and treatment patterns among patients with limited vs. extensive stage small cell lung cancer (SCLC). Methods: We identified patients with SCLC in 2017 using ICD-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d6554b3925d415fe147e2f97b660f5c3
https://doi.org/10.1200/jco.2022.40.16_suppl.e20601
Zobrazit plný text záznamu
7
Real-World Cost of Care for Commercially Insured versus Medicare Patients with Metastatic Pancreatic Cancer Who Received Guideline-Recommended Therapies
Autor: Samantha, Tomicki, Gabriela, Dieguez, Helen, Latimer, Paul, Cockrum, George, Kim
Publikováno v: Am Health Drug Benefits
BACKGROUND: Much of the literature about the costs of metastatic pancreatic cancer is focused on the Medicare population, but the cost in the commercially insured population is not well-documented. Differences in treatment patterns between commercial
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8f614aea991b9269ddc92034ea1475d7
https://pubmed.ncbi.nlm.nih.gov/34267862
Zobrazit plný text záznamu
8
Resource utilization and total cost of care among Medicare advantage patients with metastatic pancreatic cancer receiving NCCN category 1 preferred regimens
Autor: Gabriela Dieguez, Samantha Tomicki, David DeStephano, Benjamin Hsu, Paul Cockrum
Publikováno v: Journal of Clinical Oncology. 40:531-531
531 Background: Medicare Advantage accounts for almost 40% of Medicare beneficiaries in 2021. There is limited research evaluating utilization and cost for Medicare Advantage patients with metastatic pancreatic cancer (m-PANC) receiving various NCCN
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::57d36e351d6253c2b8370574feac2e01
https://doi.org/10.1200/jco.2022.40.4_suppl.531
Zobrazit plný text záznamu
9
Trends in use of one, two, and three-line NCCNcategory 1 regimens among Medicare fee-for-service (FFS) patients receiving treatment for metastatic pancreatic cancer
Autor: Gabriela Dieguez, Samantha Tomicki, Paul Cockrum, David DeStephano
Publikováno v: Journal of Clinical Oncology. 39:297-297
297 Background: There is limited research evaluating the share of patients (pts) with metastatic pancreatic cancer (m-PANC) treated according to NCCN guidelines. Methods: We identified pts with m-PANC using ICD-10 diagnosis codes in the 2016-2019 Med
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::280123e447f1b3e62220aa5cb8026131
https://doi.org/10.1200/jco.2020.39.28_suppl.297
Zobrazit plný text záznamu
10
Healthcare resource utilization, quality metrics, and costs of bladder cancer within the oncology care model
Autor: L. Johnetta Blakely, Zsolt Hepp, Jared Hirsch, Heidi S. Wirtz, Gabriela Dieguez, Rupali Fuldeore, Samantha Tomicki
Publikováno v: Journal of Clinical Oncology. 39:54-54
54 Background: The Oncology Care Model (OCM) incentivizes practices to provide higher quality, lower cost care for Medicare beneficiaries through payment arrangements that include financial and performance accountability for 6-month care episodes. We
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a284dbb7ae1602bcc5a28ea3d64d1b76
https://doi.org/10.1200/jco.2020.39.28_suppl.54
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje